Logo

Dana-Farber

ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making
Premium

The framework, which ranks de-intensification biomarkers by evidence tiers, could give oncologists, patients, regulators, and payors a common system to guide their use.

Reveal Genomics, Dana-Farber Using HER2DX to Analyze Data in Three Breast Cancer Trials

The partners aim to improve understanding of early-stage HER2-positive breast cancer patients and gain insights into optimal treatment strategies.

Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute

The firm plans to develop novobiocin for homologous recombination-deficient cancers including those resistance to PARP inhibitors.

In Brief This Week: AstraZeneca, CytoDyn, BerGenBio, Bayer, Dana-Farber Cancer Institute, Kronos Bio

News items for the week of Nov 8, 2021.

SpringWorks Therapeutics Licenses EGFR Inhibitors From Dana-Farber, Inks Two R&D Partnerships

The firm has entered collaborations with both Stanford Medicine and Ab Magnitude to further develop the new portfolio of lung cancer therapeutics.

Oct 12, 2021

MIT Spinoff Travera Looks to Validate Cell Mass as Broadly Predictive Cancer Biomarker
Premium

Aug 23, 2021

Broad Institute, Dana-Farber Open Enrollment in Cancer Research Project to All US, Canadian Patients

Jul 2, 2021

In Brief This Week: Syndax, Transgene, Sermonix, AccessHope, Achilles, Foundation Medicine

Jun 24, 2021

Researchers Make Progress in Characterizing Diverse Mechanisms of KRAS Inhibitor Resistance
Premium

May 12, 2021

Dana-Farber Cancer Institute Receives $50M Gift to Advance Pancreatic Cancer Research

Mar 3, 2021

Nonprofit Count Me In to Return Genomic Results to Patients With Rare Cancers
Premium

Feb 19, 2021

In Brief This Week: AstraZeneca, Merck, Amgen, Kintara Therapeutics, Dana Farber Cancer Institute

Jan 22, 2021

MMRF, Dana Farber Amassing Data to Develop Smoldering Multiple Myeloma Monitoring Test
Premium

Dec 3, 2020

MMRF, Dana Farber Partner on Search for Biomarkers Linked to Smoldering Multiple Myeloma Progression

Aug 10, 2020

T Cell Receptor Repertoire Linked to Anti-PD-1 Therapy Response in Hodgkin Lymphoma

Aug 4, 2020

BostonGene Partners With Dana-Farber's Weinstock Lab on T-Cell Lymphoma Biomarker Research

Jul 24, 2020

MMRF Programs Aim to Boost Precision Med Knowledge, Access in Multiple Myeloma
Premium

Jun 26, 2020

Dana-Farber Team Reports Progress With Precision Oncology Trial Matching Software

Jun 4, 2020

Studies Show Potential of Video, Online Education to Expand Cancer Risk Genetic Test Access
Premium

Jun 3, 2020

BFOR Study Uses Digital Tools to Facilitate Population BRCA Screening in Ashkenazi Jewish Community

Jun 1, 2020

MET Tyrosine Kinase Inhibitor Shows 'Encouraging' Efficacy in Phase III Kidney Cancer Trial

May 1, 2020

NCI-MATCH Data Points to Possible Role for Mutated NRAS Codon in MEK Inhibitor Response

Apr 22, 2020

Pancreatic Cancer Clinical Risk Prediction Appears to Improve With Genetic, Biomarker Data

Apr 15, 2020

Glioma Hypermutation May Not Correspond to Checkpoint Immunotherapy Response, Study Suggests

Apr 8, 2020

Esophageal Cancer Case Study Suggests Utility as Clinicians Explore Expanded Uses for Liquid Biopsy
Premium